The Question Not Asked: The Challenge of Pleiotropic Genetic Tests

Kennedy Institute of Ethics Journal

Volumn 8, Issue 2, 1998, Pages 131-144

  Wachbroit, Robert ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTICAL APPROACH; ARTICLE; BEHAVIOR; DEMENTIA; ETHICS; GENETIC COUNSELING; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETIC PRIVACY; GENETIC SCREENING; GENETICS AND REPRODUCTION; HEART DISEASE; HUMAN; INCIDENTAL FINDING; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; MANAGEMENT; MEDICAL ETHICS; MENTAL STRESS; MORALITY; MOTIVATION; PATIENT; PEDIGREE; PHYSICIAN; PROFESSIONAL PATIENT RELATIONSHIP; RISK; RISK ASSESSMENT; SOCIAL BEHAVIOR; SOCIAL PSYCHOLOGY; TIME;

ANALYTICAL APPROACH; GENETICS AND REPRODUCTION; PROFESSIONAL PATIENT RELATIONSHIP;

DEMENTIA; DISCLOSURE; DOUBLE EFFECT; ETHICS; GENETIC COUNSELING; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; GENETIC PRIVACY; GENETIC SCREENING; HEART DISEASES; HUMANS; INCIDENTAL FINDINGS; INFORMED CONSENT; INTENTION; MORAL OBLIGATIONS; MOTIVATION; PATIENTS; PEDIGREE; PHYSICIANS; POLICY MAKING; PREJUDICE; RISK; RISK ASSESSMENT; SOCIAL RESPONSIBILITY; STRESS, PSYCHOLOGICAL; TIME FACTORS; TRUTH DISCLOSURE;

EID: 0032084129     PISSN: 10546863     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. ACMG/ASHG. American College of Medical Genetics and American Society of Human Genetics Working Group on ApoE and Alzheimer Disease. 1995. Statement on Use of Apolipoprotein E Testing for Alzheimer Disease. Journal of the American Medical Association 274: 1627-29.
2. Juengst, Eric T. 1998, in press. The Ethical Implications of Alzheimer Disease Risk Testing for Other Clinical Uses of APOE Genotyping. In Genetic Testing for Alzheimer Disease: Ethical and Clinical Issues, ed. Stephen G. Post and Peter J. Whitehouse. Baltimore, MD: Johns Hopkins University Press.
3. Mayeux, Richard; Saunders, Ann M.; Shea, Steven; et al. 1998. Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease. New England Journal of Medicine 338: 506-11.
4. NIA/AA. National Institute on Aging and Alzheimer's Association Working Group. 1996. Apolipoprotein E Genotyping in Alzheimer's Disease. Lancet 347: 1091-95.
5. Post, Stephen G.; Whitehouse, Peter J.; Binstock, Robert H.; et al. 1997. The Clinical Introduction of Genetic Testing for Alzheimer Disease: An Ethical Perspective. Journal of the American Medical Association 277: 832-36.
6. Quill, Timothy E.; Dresser, Rebecca J.; and Brock, Dan W. 1997. The Rule of Double Effect - A Critique of Its Role in End-of-Life Decision Making. New England Journal of Medicine 337: 1768-71.
7. Strittmatter, W. J.; Saunders, A. M.; Schmechel, D.; et al. 1993. Apolipoprotein E: High Avidity Binding to Beta-Amyloid and Increased Frequency of Type 4 Allele in Late-Onset Familial Alzheimer Disease. Proceedings of the National Academy of Sciences 90: 1977-81.
8. Wachbroit, Robert. 1996. Disowning Knowledge: Issues in Genetic Testing. Report from the Institute for Philosophy and Public Policy 16: 14-18.
9. _, and Wasserman, David. 1995. Patient Autonomy and Value-Neutrality in Nondirective Genetic Counseling. Stanford Law & Policy Review 6: 103-12.
10. Wilson, P. W. F.; Myers, R. H.; Larson, M. G.; et al. 1994. Apolipoprotein E Alleles, Dyslipidemia, and Coronary Heart Disease. Journal of the American Medical Association 272: 1666-71.